Get the Latest Investment Ideas Delivered Straight to Your Inbox.

TICKERS: FTSV, GILD

Antibody Developer Taken Out by Gilead at 'Hefty Premium'
Research Report

Source:

The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report.

In a March 2 research note, BTIG analyst Robert Hazlett reported that Forty Seven Inc. (FTSV:NASDAQ) is being acquired by Gilead Sciences Inc. (GILD:NASDAQ) in an all cash deal. Closing is expected in Q2/20.

As a result of the announcement, BTIG increased its target price on Forty Seven from $40 per share to $95.50, the price Gilead will pay for the company, which amounts to about $4.9 billion. This reflects "a material premium over even our prior $60.48 takeout valuation, likely reflecting a very competitive process," Hazlett commented.

The California-based biopharmaceutical firm is developing anti-CD47 antibodies that will stimulate the immune system and that could be used in various cancers.

Gilead reportedly pursued Forty Seven for three key reasons, Hazlett indicated. The company's margrolimab (5F9) is at an advanced stage in the clinic, its myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) programs combining margrolimab and azacitidine are progressing and potential exists for rapid U.S. Food and Drug Administration approval of the antibody. Thus, Hazlett deduced, the Phase 1b updates on the MDS and AML programs, to be provided at the American Society of Clinical Oncology's annual meeting from May 29 to June 2, 2020, are expected to be favorable.

Hazlett noted the two catalysts for Forty Seven in Q1/20. One, the biopharma plans to start a single-arm, 100-patient trial of 5F9 in diffuse large B-cell lymphoma to evaluate overall response rate and durability. Interim data from this trial are expected in H2/20.

Two, the company will announce results from the Phase 1b ovarian cancer trial evaluating combination therapy, 5F9 and avelumab, likely the first clinical data available for 5F9 plus an anti-PD-L1. "Positive safety and efficacy data could support broader discussions for collaborations in ovarian and other cancers," noted Hazlett.

BTIG has a Buy rating on Forty Seven.

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from BTIG, Forty Seven Inc., March 2, 2020

Analyst Certification I, Robert C. Hazlett, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
I, James Colby, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues.

Company–Specific Regulatory Disclosures

BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Forty Seven, Inc. (FTSV)

BTIG LLC has received compensation for investment banking services in the past 12 months from: Forty Seven, Inc. (FTSV)

BTIG LLC had an investment banking services client relationship during the past 12 months with: Forty Seven, Inc. (FTSV)




Learn More about Which Online Broker is Right for You?

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe